Boehringer’s HERNEXEOS Approved in China as First Oral Targeted Therapy for HER2-Mutant Advanced NSCLC Read more
FDA Approves LEQEMBI IQLIK Subcutaneous Injection for Early Alzheimer’s Maintenance Therapy Read more
Heidelberg Pharma Partner Telix Pharmaceuticals Provides Regulatory Update on Imaging Agent TLX250-CDx Read more